Nicotinamide riboside is uniquely and orally bioavailable in mice and humans

Nature Communications

Volumn 7, Issue , 2016, Pages

  Trammell, Samuel A J ^a   Schmidt, Mark S ^a   Weidemann, Benjamin J ^a   Redpath, Philip ^b   Jaksch, Frank ^c   Dellinger, Ryan W ^c   Li, Zhonggang ^a   Abel, E Dale ^a   Migaud, Marie E ^a,b   Brenner, Charles ^a  

^a UNIVERSITY OF IOWA   (United States)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c ChromaDex Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CREATININE; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE RIBOSIDE; NICOTINIC ACID ADENINE DINUCLEOTIDE PHOSPHATE; NICOTINAMIDE-BETA-RIBOSIDE; NICOTINIC ACID ADENINE DINUCLEOTIDE; VITAMIN;

BIOCHEMISTRY; BIOLOGICAL UPTAKE; BIOMARKER; BLOOD; METABOLISM; PHYSIOLOGY; RODENT; VITAMIN;

ADULT; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIOACCUMULATION; BLOOD CELL COUNT; BODY MASS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG SAFETY; FEMALE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; METABOLITE; METABOLOMICS; MOUSE; NONHUMAN; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PILOT STUDY; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; URINALYSIS; ANALOGS AND DERIVATIVES; ANIMAL; BIOAVAILABILITY; BLOOD; C57BL MOUSE; CHEMISTRY; LIVER; METABOLISM; METABOLOME; MIDDLE AGED; MONONUCLEAR CELL; ORAL DRUG ADMINISTRATION; URINE;

MUS;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BIOMARKERS; HUMANS; LEUKOCYTES, MONONUCLEAR; LIVER; MALE; METABOLOME; MICE, INBRED C57BL; MIDDLE AGED; NAD; NIACINAMIDE; VITAMINS;

EID: 84991372712     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12948     Document Type: Article

References (57)

1. Belenky, P., Bogan, K. L. & Brenner, C. NAD(+) metabolism in health and disease. Trends. Biochem. Sci. 32, 12-19 (2007).
2. Bogan, K. L. & Brenner, C. Nicotinic acid, nicotinamide and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu. Rev. Nutr. 28, 115-130 (2008).
3. Bouchard, V. J., Rouleau, M. & Poirier, G. G. PARP-1, a determinant of cell survival in response to DNA damage. Exp. Hematol. 31, 446-454 (2003).
4. Finkel, T., Deng, C. X. & Mostoslavsky, R. Recent progress in the biology and physiology of sirtuins. Nature 460, 587-591 (2009).
5. Okamoto, H., Takawasa, S. & Sugawara, A. The CD38-cyclic ADP-ribose system in mammals: historical background, pathophysiology and perspective. Messenger 3, 27-24 (2014).
6. Bieganowski, P. & Brenner, C. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell 117, 495-502 (2004).
7. Trammell, S. A., Yu, L., Redpath, P., Migaud, M. E. & Brenner, C. Nicotinamide riboside is a major NAD+ precursor vitamin in cow milk. J. Nutr. 146, 957-963 (2016).
8. Evans, C. et al. NAD+ metabolite levels as a function of vitamins and calorie restriction: evidence for different mechanisms of longevity. BMC Chem. Biol. 10, 2 (2010).
9. Trammell, S. A. & Brenner, C. Targeted, LCMS-based metabolomics for quantitative measurement of NAD metabolites. Comput. Struct. Biotechnol. J. 4, e201301012 (2013).
10. Gazzaniga, F., Stebbins, R., Chang, S. Z., McPeek, M. A. & Brenner, C. Microbial NAD metabolism: lessons from comparative genomics. Microbiol. Mol. Biol. Rev. 73, 529-541 (2009).
11. Elvehjem, C. A., Madden, R. J., Strong, F. M. & Woolley, D. W. The isolation and identification of the anti-black tongue factor. J. Biol. Chem. 123, 137-149 (1938).
12. Koehn, C. J. & Elvehjem, C. A. Further studies on the concentration of the antipellagra factor. J. Biol. Chem. 118, 693-699 (1937).
13. Conze, D. B., Crespo-Barreto, J. & Kruger, C. L. Safety assessment of nicotinamide riboside, a form of vitamin B3. Hum. Exp. Toxicol. doi:10.1177/0960327115626254 (2016).
14. Zamporlini, F. et al. Novel assay for simultaneous measurement of pyridine mononucleotides synthesizing activities allows dissection of the NAD(+) biosynthetic machinery in mammalian cells. FEBS J. 281, 5104-5119 (2014).
15. Mori, V. et al. Metabolic profiling of alternative NAD biosynthetic routes in mouse tissues. PLoS ONE 9, e113939 (2014).
16. Brenner, C. Metabolism: targeting a fat-accumulation gene. Nature 508, 194-195 (2014).
17. Ramsey, K. M. et al. Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis. Science 324, 651-654 (2009).
18. Nakahata, Y., Sahar, S., Astarita, G., Kaluzova, M. & Sassone-Corsi, P. Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1. Science 324, 654-657 (2009).
19. Yoshino, J., Mills, K. F., Yoon, M. J. & Imai, S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 14, 528-536 (2011).
20. Gomes, A. P. et al. Declining NAD(+) induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell 155, 1624-1638 (2013).
21. Braidy, N. et al. Mapping NAD(+) metabolism in the brain of ageing Wistar rats: potential targets for influencing brain senescence. Biogerontology 15, 177-198 (2014).
22. Verdin, E. NAD+ in aging, metabolism, and neurodegeneration. Science 350, 1208-1213 (2105).
23. DiPalma, J. R. & Thayer, W. S. Use of niacin as a drug. Annu. Rev. Nutr. 11, 169-187 (1991).
24. Kuvin, J. T. et al. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am. J. Cardiol. 98, 743-745 (2006).
25. Bitterman, K. J., Anderson, R.M., Cohen, H. Y., Latorre-Esteves,M. & Sinclair, D. A. Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast Sir2 and human SIRT1. J. Biol. Chem. 277, 45099-45107 (2002).
26. Belenky, P. et al. Nicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Urh1/Pnp1/Meu1 pathways to NAD(+). Cell 129, 473-484 (2007).
27. Canto, C. et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 15, 838-847 (2012).
28. Brown, K. D. et al. Activation of SIRT3 by the NAD+ precursor nicotinamide riboside protects from noise-induced hearing loss. Cell Metab. 20, 1059-1068 (2014).
29. Zhang, H. et al. NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice. Science 352, 1436-1443 (2016).
30. Trammell, S. A. J. et al. Nicotinamide riboside opposes Type 2 diabetes and neuropathy in mice. Sci. Rep. 6, 26933 (2016).
31. Nikiforov, A., Dolle, C., Niere, M. & Ziegler, M. Pathways and subcellular compartmentation of NAD biosynthesis in human cells: from entry of extracellular precursors to mitochondrial NAD generation. J. Biol. Chem. 286, 21767-21778 (2011).
32. Brenner, C. Boosting NAD to spare hearing. Cell Metab. 20, 926-927 (2014).
33. Canto, C., Menzies, K. J. & Auwerx, J. NAD(+) metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metab. 22, 31-53 (2015).
34. Belenky, P., Christensen, K. C., Gazzaniga, F. S., Pletnev, A. & Brenner, C. Nicotinamide riboside and nicotinic acid riboside salvage in fungi and mammals: quantitative basis for Urh1 and purine nucleoside phosphorylase function in NAD+ metabolism. J. Biol. Chem. 284, 158-164 (2009).
35. Bieganowski, P., Pace, H. C. & Brenner, C. Eukaryotic NAD+ synthetase Qns1 contains an essential, obligate intramolecular thiol glutamine amidotransferase domain related to nitrilase. J. Biol. Chem. 278, 33049-33055 (2003).
36. Wojcik, M., Seidle, H. F., Bieganowski, P. & Brenner, C. Glutamine-dependent NAD+ synthetase: how a two-domain, three-substrate enzyme avoids waste. J. Biol. Chem. 281, 33395-33402 (2006).
37. Langan, Jr T. A., Kaplan, N. O. & Shuster, L. Formation of the nicotinic acid analogue of diphosphopyridine nucleotide after nicotinamide administration. J. Biol. Chem. 234, 2161-2168 (1959).
38. Collins, P. B. & Chaykin, S. The management of nicotinamide and nicotinic acid in the mouse. J. Biol. Chem. 247, 778-783 (1972).
39. Grunicke, H., Keller, H. J., Liersch, M. & Benaguid, A. New aspects of the mechanism and regulation of pyridine nucleotide metabolism. Adv. Enzyme. Regul. 12, 397-418 (1974).
40. Reagan-Shaw, S., Nihal, M. & Ahmad, N. Dose translation from animal to human studies revisited. FASEB J. 22, 659-661 (2008).
41. Tempel, W. et al. Nicotinamide riboside kinase structures reveal new pathways to NAD+ . PLoS Biol. 5, e263 (2007).
42. Hong, S. et al. Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. Nat. Med. 21, 887-894 (2015).
43. Trammell, S. A. & Brenner, C. NNMT: a bad actor in fat makes good in liver. Cell Metab. 22, 200-201 (2015).
44. Altschul, R., Hoffer, A. & Stephen, J. D. Influence of nicotinic acid on cholesterol in man. Arch. Biochem. Biophys. 54, 558-559 (1955).
45. Imai, S. & Guarente, L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 24, 464-471 (2014).
46. Mills, E. et al. The safety of over-the-counter niacin. A randomized placebocontrolled trial [ISRCTN18054903]. BMC Clin. Pharmacol. 3, 4 (2003).
47. Norquist, J. M. et al. Validation of a questionnaire to assess niacin-induced cutaneous flushing. Curr. Med. Res. Opin. 23, 1549-1560 (2007).
48. Ratajczak, J. et al. NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. Nat. Commun. 7, 13103 doi: 10.1038/ncomms13103 (2016).
49. Preiss, J. & Handler, P. Biosynthesis of diphosphopyridine nucleotide II. Enzymatic aspects. J. Biol. Chem. 233, 493-500 (1958).
50. Guse, A. H. Calcium mobilizing second messengers derived from NAD. Biochim. Biophys. Acta. 1854, 1132-1137 (2015).
51. Kolodziejska-Huben, M., Kaminski, Z. & Paneth, P. Synthesis of 18O-labelled nicotinamide. J. Labelled Comp. Radiopharm. 45, 1-6 (2002).
52. Yang, T., Chan, N. Y. & Sauve, A. A. Syntheses of nicotinamide riboside and derivatives: effective agents for increasing nicotinamide adenine dinucleotide concentrations in mammalian cells. J. Med. Chem. 50, 6458-6461 (2007).
53. Hovener, J. B. et al. Toward biocompatible nuclear hyperpolarization using signal amplification by reversible exchange: quantitative in situ spectroscopy and high-field imaging. Anal. Chem. 86, 1767-1774 (2014).
54. Chatterjee, A., Hazra, A. B., Abdelwahed, S., Hilmey, D. G. & Begley, T. P. A radical dance in thiamin biosynthesis: mechanistic analysis of the bacterial hydroxymethylpyrimidine phosphate synthase. Angew. Chem. Int. Ed. Engl. 49, 8653-8656 (2010).
55. Fouquerel, E. et al. ARTD1/PARP1 negatively regulates glycolysis by inhibiting hexokinase 1 independent of NAD+ depletion. Cell Rep. 8, 1819-1831 (2014).
56. Altman, L. K. Who Goes First: The Story of Self-experimentation in Medicine (University of California Press, 1987).
57. Nedelman, J. R., Gibiansky, E. & Lau, D. T. Applying Bailers method for AUC confidence intervals to sparse sampling. Pharm. Res. 12, 124-128 (1995).